Generation Bio Co. (GBIO) Stock

About Generation Bio Co.

Generation Bio Co. is a biotechnology firm focused on genetic therapies, working to devise treatments for both uncommon and widespread diseases. The company's current development pipeline includes multiple projects, with a particular emphasis on addressing rare and prevalent conditions affecting the liver and retina. Additionally, it directs its research towards disorders of skeletal muscle, the central nervous system, and oncology. The enterprise, which was initially established as Torus Therapeutics, Inc., adopted its current name, Generation Bio Co., in November 2017. Incorporated in 2016, its main operations are based in Cambridge, Massachusetts.

Generation Bio Co. is headquartered in US.

Generation Bio Co. (GBIO) stock trades at $5.34 with a market capitalization of $35.98M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.87, reflecting a net loss over the last twelve months, price-to-book of 0.71, price-to-sales of 3.25. Over the past 52 weeks the stock has ranged between $3.00 and $7.52, and currently trades 29.0% below its 52-week high.

On profitability, Generation Bio Co. generates a return on equity (ROE) of -69.52% (negative, reflecting a net loss), return on capital employed of -60.50%, an operating margin of -550.62%, a net profit margin of -372.18%.

Official website: generationbio.com

Generation Bio Co. by the numbers, 2018–2024

Between 2018 and 2024 Generation Bio Co. reported revenue of $0 rising to $20.0M. Compounded, revenue has grown —% a year over five years, —% over three, 233.3% over the last twelve months. Net profit fell to $-132.0M.

Operating margin went from -103594.4% in 2018 to -715.8% in 2024, a gain of 102878.6 percentage points. The most recent net margin is -372.18%. On a trailing twelve-month basis to Sep '25, revenue is $16.0M and net profit $-63.0M.

Borrowings stand at $94.0M, cash on hand is $89.6M, cash from operations was $-89.0M in the latest year, positive in 0 of the last 7.

Return on equity has averaged -65.2% over five years, and was -153.5% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Generation Bio Co. (GBIO) — frequently asked questions